1887

Abstract

SUMMARY: The class 1 outer-membrane protein of is the target for subtype-specific, bactericidal monoclonal antibodies (mAbs). The epitopes recognized by these antibodies have been mapped previously to linear peptides corresponding to the sequences thought to be exposed at the apices of surface-exposed loops of the protein. In this work several synthetic peptides containing the subtype PI. 16b epitope have been synthesized with the aim of inducing a polyclonal immune response resembling the reactivity of the mAbs. Initially, peptides of 9 and 15 amino acid residues were synthesized and used for immunization after coupling to a carrier protein. The reactivity of the resulting antisera, with synthetic linear decapeptides, resembled that seen in previous epitope mapping experiments with the protective mAbs. However, despite the induction of antibodies having the desired specificity, the antisera reacted poorly with the native protein in outer membranes, and were non-bactericidal. A 36mer peptide, consisting of the entire surface-exposed loop 4 of the class 1 protein was then synthesized and used for immunization as (i) free peptide, (ii) peptide coupled to carrier and (iii) peptide subjected to cyclization, in an attempt to restrict it to conformations that might more closely resemble the native loop structure. In contrast to antisera raised against linear peptides, antibodies raised by immunization with the 36mer cyclic peptide, did not react with linear peptides recognized by the mAbs, but instead appeared to recognize conformational determinants. This antiserum promoted complement-mediated bactericidal killing of the homologous meningococcal strain, demonstrating the potential of synthetic peptide immunogens for inducing a protective immune response against group B meningococci.

Loading

Article metrics loading...

/content/journal/micro/10.1099/00221287-139-8-1729
1993-08-01
2021-10-28
Loading full text...

Full text loading...

/deliver/fulltext/micro/139/8/mic-139-8-1729.html?itemId=/content/journal/micro/10.1099/00221287-139-8-1729&mimeType=html&fmt=ahah

References

  1. Amador R., Moreno A., Valero V., Murillo L., Mora A.L., Rojas M., Rocha C., Salcedo M, Espejo F., Nunez F., Patarroyo M.E. 1992; The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.. Vaccine 10:179–184
    [Google Scholar]
  2. Arnon R. 1991; Synthetic peptides as the basis for vaccine design.. Molecular Immunology 28:209–215
    [Google Scholar]
  3. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.K., Nokleby H., Rosenqvist E., Solberg L.K., Closs O., Eng J., Froholm L.O., Lystad A., Bakketeig L.S., Hareide B. 1991; Effect of outer- membrane vesicle vaccine against group-B meningococcal disease in Norway.. Lancet 338:1093–1096
    [Google Scholar]
  4. Elkins C., Carbonetti N.H., Varela V.A., Stirewalt D., Klapper D.G., Sparling P.F. 1992; Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated.. Molecular Microbiology 6:2617–2628
    [Google Scholar]
  5. Frasch C.E. 1985; Status of a group-B Neisseria meningitidis vaccine.. European Journal of Clinical Microbiology 4:533–536
    [Google Scholar]
  6. Frasch C.E., Zollinger W.D., Poolman J.T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.. Review of hzfectious Diseases 7:504–510
    [Google Scholar]
  7. Geysen H.M., Rodda S.J., Mason T.J., Tribbick G., Schoofs P.G. 1987; Strategies for epitope analysis using peptide synthesis.. Journal of Immunological Methods 102:259–274
    [Google Scholar]
  8. Goldschneider I., Gotschlich E.C., Artenstein M.S. 1969; Human immunity to the meningococcus.II.Development of natural immunity.. Journal of Experimental Medicine 129:1327–1348
    [Google Scholar]
  9. Heckels J.E. 1981; Structural comparison of Neisseria gonorrhoeae outer-membrane proteins.. Journal of Bacteriology 145:736–742
    [Google Scholar]
  10. Heckels J.E., Virji M., Tinsley C.R. 1990; Vaccination against gonorrhoea - the potential protective effect of immunization with a synthetic peptide containing a conserved epitope of gonococcal outer membrane protein lb.. Vaccine 8:225–230
    [Google Scholar]
  11. Lambden P.R., Robertson J.N., Watt P.J. 1981; The preparation and properties of α-pili and β-pili from variants of Neisseria gonorrhoeae P9.. Journal of General Microbiology 124:109–117
    [Google Scholar]
  12. Van DER LEY P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. 1991; Topology of outer-membrane porins in pathogenic Neisseria spp.. Infection and Immunity 59:2963–2971
    [Google Scholar]
  13. Mcguinness B.T., Barlow A.K., Clarke I.N., Farley J.E., Anilionis A.POOLMAN, Heckels J.E. 1990; Deduced amino acid sequences of class 1 protein (PorA) from 3 strains of Neisseria meningitidis - synthetic peptides define the epitopes responsible for serosubtype specificity.. Journal of Experimental Medicine 171:1871–1882
    [Google Scholar]
  14. Mcguinness B.T., Clarke I.N., Lambden P.R., Barlow A.K., Poolman J.T., Jones D.M., Heckels J.E. 1991; Point mutation in meningococcal por A gene associated with increased endemic disease.. Lancet 337:514–517
    [Google Scholar]
  15. Mcguinness B.T., Lambden P.R., Heckels J.E. 1993; Class 1 outer membrane protein of Neisseria meningitidis : epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology.. Molecular Microbiology 7:505–514
    [Google Scholar]
  16. Maiden M.C.J., Suker J., Mckenna A.J., Bygraves J.A., Feavers I.M. 1991; Comparison of the class 1 outer membrane proteins of 8 serological reference strains of Neisseria meningitidis.. Molecular Microbiology 5:727–736
    [Google Scholar]
  17. Meloen R.H, Hage-VANNOORT M., Langedijk J.P.M., Posthumus W.P.A., Puyk W.C., Lenstra J.A., Langeveld J.P.M. 1991; The use of peptides to reconstruct conformational determinants: a brief review.. Amales De Biologie Clinique 49:231–242
    [Google Scholar]
  18. Demoraes J.C., Perkins B.A., Camargo M.C.C., Hidalgo N.T.R., Barbosa H.A., Sacchi C.T., Gral I.M.L., Gaitas V.L., Vasconcelos H.D., Plikaytis B.D., Wenger J.D., Broome C.V. 1992; Protective efficacy of a serogroup-B meningococcal vaccine in Sao-Paulo, Brazil.. Lancet 340:1074–1078
    [Google Scholar]
  19. Munkley A., Tinsley C.R., Virji M., Heckels J.E. 1991; Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein.. Microbial Pathogenesis 11:447–452
    [Google Scholar]
  20. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. 1989; Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat in vitro bactericidal assay.. Vaccine 7:325–328
    [Google Scholar]
  21. Sierra G.V.G., Campa H.C, Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., Casanueva G.V., Rico C.O., Rodriguez C.R., Terry M.H. 1991; Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.. NIPH Annals 14:195–210
    [Google Scholar]
  22. Tam J.P., Lu Y.A. 1989; Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T-cell and B-cell epitopes.. Proceedings of the National Academy of Sciences of the United States of America 869084–9088
    [Google Scholar]
  23. Tinsley C.R., Heckels J.E. 1986; Variation in the expression of pili and outer-membrane protein by Neisseria meningitidis during the course of meningococcal infection.. Journal of General Microbiology 132:2483–2490
    [Google Scholar]
  24. Tsai C.M., Frasch C.E., Mocca L.F. 1981; Five structural classes of major outer membrane proteins in Neisseria meningitidis.. Journal of Bacteriology 146:69–78
    [Google Scholar]
  25. Virji M., Heckels J.E. 1989; Location of a blocking epitope on outer-membrane protein-III of Neisseria gonorrhoeae by synthetic peptide analysis.. Journal of General Microbiology 135:1895–1899
    [Google Scholar]
  26. Wedege E., Froholm L.O. 1986; Human-antibody response to a group-B serotype 2a meningococcal vaccine determined by immunoblotting.. Infection and Immunity 51:571–578
    [Google Scholar]
  27. Wiertz E.J.H.J., Vangaans-VANDENBRINK J.A.M., Gausepohl H., Prochnicka-CHALUFOUR A., Hoogerhout P., Poolman J.T. 1992; Identification of T-cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide-synthesis.. Journal of Experimental Medicine 176:79–88
    [Google Scholar]
  28. Zollinger W., Boslego J., Moran E., Garcia J., Ruiz S., Brandt B., Martinez M., Arthur J., Underwood P., Hankins W., Mays J., Gilly J. THE CHILEAN NATIONAL COMMITTEE FOR MENINGOCOCCAL DISEASE 1991; Meningococcal serogroup B vaccine: protection trial and follow-up studies in Chile.. NIPH Annals 14:211–213
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/00221287-139-8-1729
Loading
/content/journal/micro/10.1099/00221287-139-8-1729
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error